Pharmaceuticals

Rising Prevalence Of Chronic Diseases Driving Growth In The Oral Biologics And Biosimilar Drugs Is Supporting Expansion In The Cosentyx Drug Market

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Cosentyx Drug Market During 2026–2030?

The cosentyx drug market has seen substantial expansion in its size over recent years. It is projected to increase from $5.68 million in 2025 to $6.21 million in 2026, at a compound annual growth rate (CAGR) of 9.2%. Historically, this growth can be attributed to the approval of IL-17 inhibitors, the high prevalence of psoriasis and arthritis, a limited response to TNF inhibitors, adoption by specialist dermatology, and the development of biologic treatment guidelines.

The Cosentyx drug market is projected to experience robust expansion in the upcoming years. By 2030, this market is anticipated to reach a valuation of $8.74 million, demonstrating a compound annual growth rate (CAGR) of 8.9%. Factors contributing to this growth during the projected period include a rise in autoimmune disease diagnoses, broadened treatment applications, heightened patient understanding, enhanced availability of biologics, and supportive long-term efficacy data. Key trends observed within this forecast span are the increasing acceptance of IL-17 inhibitor therapies, wider application across various autoimmune conditions, a move towards specific biologic treatments, greater utilization of prolonged maintenance therapy, and a surging demand for self-injectable biologics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp

What Leading Drivers Are Supporting The Cosentyx Drug Market Expansion?

The Cosentyx market is anticipated to grow as the occurrence of autoimmune diseases increases. These disorders are characterized by the immune system mistakenly attacking the body’s healthy cells and tissues. The rising prevalence of autoimmune diseases is linked to genetic predispositions, environmental factors such as infections and pollutants, and changes in lifestyle, including heightened stress and dietary shifts. Cosentyx (secukinumab) aids patients suffering from autoimmune diseases by targeting and inhibiting interleukin-17A, a key cytokine involved in inflammation, thereby reducing symptoms, improving quality of life, and effectively managing conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, data from Public Health Scotland, a Scotland-based national organization, indicated in August 2024 that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients in 2023. Thus, the growing prevalence of autoimmune diseases is a significant driver for the Cosentyx market.

How Is Segmentation Applied In The Cosentyx Drug Market Segment Analysis?

The cosentyx drug market covered in this report is segmented –

1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis

2) By Route Of Administration: Subcutaneous injection, Intravenous infusion

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

What Market Trends Are Affecting The Cosentyx Drug Market?

Key companies within the Cosentyx drug market are directing their efforts towards creating advanced therapeutic approaches, particularly biological treatment options, to address unmet medical requirements, improve treatment effectiveness, and deliver precise therapies for managing chronic autoimmune conditions. This strategy aims to solidify their market standing and serve an increasing number of patients. Biologic treatments are sophisticated therapies derived from living organisms or their cells, specifically designed to target elements of the immune system, such as interleukin-17A, to regulate inflammatory responses and effectively manage autoimmune conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis. For example, in October 2023, Novartis AG, a pharmaceutical company based in Switzerland, obtained FDA approval for Cosentyx (secukinumab), making it the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in almost a decade. This approval represents a substantial leap forward in the treatment possibilities for HS, a persistent and often incapacitating skin condition characterized by painful lumps that can lead to scarring and psychological distress.

Who Are The Companies Participating In The Cosentyx Drug Market Environment?

Major companies operating in the cosentyx drug market are Novartis AG

Get The Full Cosentyx Drug Market Report:

https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report

Which Region Leads The Cosentyx Drug Market In Overall Market Size?

North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cosentyx Drug Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report

Browse Through More Reports Similar to the Global Cosentyx Drug Market 2026, By The Business Research Company

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Pharmaceutical Label Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795